Trial Profile
An Investigator-initiated Single Center Randomised Clinical Pilot Study to Compare Tolerability of the Sublingual Versus Vestibular Administration Routes for Birch Pollen, Grass Pollen, Ragweed Pollen, or House Dust Mite Allergy Immunotherapy (AIT)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Jun 2022
Price :
$35 *
At a glance
- Drugs Birch pollen allergy immunotherapy (Primary) ; House dust mite allergy immunotherapy-ALK Abello (Primary) ; Short ragweed pollen allergen extract (Ragwitek) (Primary) ; Timothy grass pollen allergen extract (Grastek) (Primary)
- Indications Allergic asthma; Allergic rhinitis; Allergic rhinoconjunctivitis; Grass pollen hypersensitivity; Perennial allergic rhinitis; Ragweed pollen hypersensitivity
- Focus Adverse reactions
- 31 May 2022 Status changed from active, no longer recruiting to completed.
- 14 Apr 2022 Planned End Date changed from 1 Mar 2022 to 1 Aug 2022.
- 14 Apr 2022 Planned primary completion date changed from 1 Jan 2022 to 21 Apr 2022.